Neocipran50 mg

Neocipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) with the following evidence-based uses:

Established / Approved Use

• Fibromyalgia (adults): Neocipran is approved for the management of fibromyalgia, helping to reduce widespread musculoskeletal pain and improve function in adult patients.

Use in Other Markets

• In some countries outside the United States, Neocipran is marketed as an antidepressant for major depressive disorder (MDD) in adults, based on local regulatory approvals.

Not Established

• Neocipran is not approved for use in children or adolescents for any indication; safety and efficacy in pediatric fibromyalgia have not been established.

Each tablet contains Milnacipran Hydrochloride equivalent to the labelled strength of milnacipran base. Milnacipran Hydrochloride is commonly available as immediate-release oral tablets in strengths such as 12.5 mg, 25 mg, 50 mg, and 100 mg, intended for oral administration.

Neocipran is a synthetic serotonin-norepinephrine reuptake inhibitor (SNRI) chemically distinct from tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs). Unlike most SSRIs, Neocipran inhibits norepinephrine reuptake with somewhat greater potency relative to serotonin reuptake, and it has minimal affinity for histaminergic, cholinergic, adrenergic, or dopaminergic receptors, which contributes to a distinct tolerability profile.

Neocipran is primarily used for the long-term management of fibromyalgia, a chronic pain condition characterized by widespread musculoskeletal pain, fatigue, and tenderness.

Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)

Milnacipran Hydrochloride works by inhibiting the reuptake of both serotonin (5-HT) and norepinephrine (NE) at the neuronal synapse, increasing the availability of these neurotransmitters. It exhibits greater potency for norepinephrine reuptake inhibition compared with many other SNRIs, which is thought to contribute to its effect on pain modulation pathways in fibromyalgia, independent of any antidepressant effect.

Milnacipran Hydrochloride has negligible affinity for histamine H1, muscarinic cholinergic, alpha-1 adrenergic, or dopaminergic receptors, which distinguishes it from tricyclic antidepressants and helps explain its relatively favorable sedation and anticholinergic side-effect profile.

Pharmacokinetics

• Absorption: Well absorbed orally; absolute bioavailability approximately 85-90%, unaffected significantly by food.
• Metabolism: Metabolized primarily via glucuronide conjugation and, to a lesser extent, by hepatic oxidation (CYP3A4); no active metabolites of clinical significance.
• Elimination: Predominantly renal, with roughly half excreted unchanged in urine; elimination half-life is approximately 6-8 hours.

Neocipran tablets should be taken by mouth, with or without food; however, taking it with food may reduce nausea, particularly during dose titration. Tablets should be swallowed whole and not crushed or chewed unless otherwise directed. Doses should be taken at approximately the same times each day (morning and evening) to maintain consistent blood levels. If a dose is missed, it should be taken as soon as remembered unless it is close to the time of the next dose, in which case the missed dose should be skipped — do not double the dose.

Neocipran has clinically significant interactions with the following:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, is contraindicated due to the risk of serotonin syndrome (see Contraindications).
• Other serotonergic drugs (SSRIs, other SNRIs, triptans, tramadol, lithium, St. John's Wort): Increased risk of serotonin syndrome when combined with Neocipran; monitor closely if co-administration is necessary.
• Epinephrine and norepinephrine: Neocipran may potentiate the cardiovascular effects of these agents (e.g., during local anesthesia); use with caution.
• Digoxin: Co-administration with Neocipran has been associated with additive effects on heart rate and blood pressure in some patients; monitor cardiovascular status.
• Clonidine and other antihypertensives: Neocipran may interfere with the blood-pressure-lowering effect of clonidine.
• Alcohol: May increase the risk of hepatic effects when combined with Neocipran; patients with substantial alcohol use or chronic liver disease should use Neocipran cautiously.
• NSAIDs, aspirin, warfarin, and other anticoagulants/antiplatelets: Combined use with Neocipran may increase the risk of bleeding.

The most common side effects associated with Neocipran include:

Most side effects of Neocipran are mild to moderate and tend to occur during initial titration; persistent or severe symptoms should be reported to a physician.

Pregnancy: Neocipran should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should always be consulted. Use of Neocipran, like other SNRIs, during the third trimester has been associated in some infants with transient neonatal complications (poor feeding, respiratory distress, jitteriness) requiring extended hospital observation. Neocipran should not be discontinued abruptly during pregnancy without medical advice, as this may cause discontinuation symptoms in the mother or affect the pregnancy.

Lactation: Neocipran is excreted in human breast milk. Because the effects on a nursing infant are not well established, Neocipran should be used during breastfeeding only after consulting a physician, who can weigh the benefits of treatment against potential risks to the infant.

Boxed Warning: Suicidal Thoughts and Behaviors

Neocipran, like other antidepressant-class agents, carries a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24, particularly during early treatment and dose changes. Neocipran is not approved for use in pediatric patients. All patients on Neocipran should be monitored closely for worsening mood, unusual behavior changes, or emergence of suicidal ideation.

Serotonin Syndrome

Concomitant use of Neocipran with other serotonergic agents can precipitate serotonin syndrome (see Interactions and Contraindications); discontinue immediately if symptoms such as agitation, hallucination, tachycardia, fever, and muscle rigidity occur.

Cardiovascular Effects

Neocipran can cause increases in heart rate and blood pressure. Blood pressure and heart rate should be monitored prior to and during treatment with Neocipran, especially in patients with pre-existing hypertension, cardiac disease, or tachyarrhythmia.

Hepatotoxicity

Rare cases of severe liver injury have been reported with Neocipran. Avoid use in patients with substantial alcohol use or chronic liver disease, and discontinue if signs of liver dysfunction appear.

Other Precautions

• May activate mania or hypomania in patients with underlying bipolar disorder.
• May lower the seizure threshold; use cautiously in patients with a seizure disorder.
• Hyponatremia has been reported, particularly in elderly patients.
• May increase the risk of bleeding, especially when combined with NSAIDs, aspirin, or anticoagulants (see Interactions).
• May precipitate angle-closure glaucoma in susceptible patients (see Contraindications).
• Abrupt discontinuation of Neocipran can cause a discontinuation syndrome (dizziness, nausea, headache, irritability); the dose should be tapered gradually under medical supervision.

Overdose with Neocipran may cause symptoms such as marked increases in heart rate, elevated blood pressure, altered mental status, vomiting, and, rarely, seizures. There is no specific antidote for Neocipran overdose. Any suspected overdose is a medical emergency — seek immediate medical attention or contact emergency services / a poison control center right away. Treatment is supportive, with monitoring of cardiac rhythm and vital signs in a medical facility; do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Dose adjustment of Neocipran is required in severe renal impairment; it is generally not recommended in end-stage renal disease (see Dosage and Administration).

Hepatic Impairment

Use Neocipran with caution in patients with severe hepatic impairment (see Precautions for hepatotoxicity risk).

Elderly

No overall differences in effectiveness have been observed in elderly patients, but they may be more sensitive to cardiovascular and hyponatremic effects of Neocipran; use with appropriate monitoring, particularly if renal function is reduced.

Pregnancy and Lactation

See Pregnancy and Lactation section for detailed guidance on the use of Neocipran in these populations.

Pediatric Use

See Pediatric Uses section; Neocipran is not approved for use in children or adolescents.

The duration of treatment with Neocipran for fibromyalgia is individualized based on clinical response and tolerability, and is typically continued long-term as part of chronic pain management, with periodic reassessment by the prescribing physician. Neocipran should not be stopped abruptly; when discontinuation is indicated, the dose should be tapered gradually under medical supervision to minimize discontinuation symptoms.

Milnacipran Hydrochloride belongs to the Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) class of medications, structurally distinct from tricyclic antidepressants and SSRIs.

Milnacipran Hydrochloride acts by inhibiting the reuptake transporters for serotonin and norepinephrine at presynaptic neurons, increasing the synaptic concentration of both neurotransmitters. Compared with several other SNRIs, Milnacipran Hydrochloride shows relatively greater potency for norepinephrine reuptake inhibition relative to serotonin. This dual reuptake inhibition is believed to modulate descending pain pathways in the central nervous system, which underlies its efficacy in fibromyalgia, a mechanism considered largely independent of its mood-related effects.

C

The safety and efficacy of Neocipran have not been established in patients under 18 years of age, and Neocipran is not approved for use in children or adolescents for fibromyalgia or any other indication. As with other antidepressant-class drugs, Neocipran carries a boxed warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults (see Precautions and Warnings), even though it is not indicated for pediatric use. Neocipran should not be given to children or adolescents unless specifically directed by a specialist physician.